My man, how many times do you need to be shown the same thing before it sinks in?
I have linked this systematic review detailing all P1 trials conducted prior to 2020 for Oncolytic Viruses multiple times: Clinical Application of Oncolytic Viruses- A Systematic Review.pdf
I collated all the compounds that achieved a response from the phase 1 section alongside CF33. Plenty of OV therapies are contained within that list achieved a CR and none of them have been successful commercially. Even CG0070 is still in clinical development after a near 50% CR rate in Bladder cancer at P1 - Why? Because the market is extremely competitive.
My man, how many times do you need to be shown the same thing...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.005(0.41%) |
Mkt cap ! $212.8M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.26 | $1.22 | $67.00K | 53.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2078 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 10000 | 1 |
View Market Depth
| Last trade - 15.11pm 25/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |